Foxchart.com
Pluristem Therapeutics Inc. (PSTI)
1  -0.03 (-2.91%)  07-26 00:00
Open: 1.02
High: 1.0401
Low: 0.9595
Volume: 170,627
Market Cap: 41(M)
PE Ratio: -0.68
Exchange: NASDAQ Global Market
Industry: Biotechnology
Sector: Healthcare
Technical analysis
Rating Flag Rating Flag Rating Flag Rating Flag Rating Flag
sell buy
Resistance 2: 1.21
Resistance 1: 1.04
Pivot price: 1.00
Support 1: 0.99
Support 2: 0.96
52w High:
52w Low:
Watchlist
MSFT0 (0%)
TWTR0 (0%)
BAC0 (0%)
AMZN0 (0%)
FB0 (0%)
GM0 (0%)
Zoom in Zoom out
Draw lines
Horizontal lines
Parallel lines
Fibonacci lines
Remove studies
Shot and share

Pluristem Therapeutics Inc. operates as a bio-technology company. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders. The company develops placental expanded (PLX) based cell therapy products, including PLX-PAD that is in Phase III clinical trial for the recovery after surgery for hip fracture; in Phase II clinical trail for the treatment of acute respiratory distress syndrome associated with COVID-19; and in Phase I/II clinical trial for treatment of steroid-refractory graft versus host disease. It also develops PLX-R18, which has completed Phase I clinical trial incomplete hematopoietic recovery following hematopoietic cell transplantation, as well as conducts various animal studies for the evaluation of PLX-R18 for the treatment of acute radiation syndrome. The company has a license agreement for conducting clinical trials of PLX-PAD product in South Korea. It also has a collaborative project nTRACK, that examines gold nano particles labeling of stem cells; and has collaboration agreement with the NASA's Ames Research Center to evaluate the potential of PLX cell therapies in preventing and treating medical conditions caused during space missions. Pluristem Therapeutics Inc. was incorporated in 2001 and is based in Haifa, Israel.

Financials
EPS -46050000.000
Book Value 0.000
PEG Ratio 0.00
Gross Profit 0.000
Profit Margin (%) 0.00
Operating Margin (%) -20.00
Return on Assets (ttm) 212.8
Return on Equity (ttm) -37.3
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
×
Share on Facebook Tweet this page

Foxchart international:  |  United States  |  Canada  |  United Kingdom  |  Australia  |  New Zealand  |  Singapore  |  India

©Foxchart.com All Rights Reserved. Foxchart.com | United States NYSE NASDAQ AMEX stock markets, stock quotes and stock technical analysis charts. Data and information is provided for informational purposes only, is not intended for trading purposes and is not investment advice. Neither Foxchart.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Market data provided by: IEX